We report the first case of an allogeneic stem cell transplant using a donor with essential thrombocythaemia (ET) with subsequent attainment of complete remission (CR) and no manifestation of ET in the recipient. A 48-year-old man presented with poor prognosis stage III multiple myeloma (MM) in October 2001. Immunoglobulin (Ig) G level was 72 g/l with monoclonal IgG paraprotein and free monoclonal lambda light chains in serum and urine. Bone marrow examination revealed 58% plasma cells with blastic morphology. Skeletal survey was normal, but b 2 -microglobulin was raised at 5.97 mg/l. He received chemotherapy with six courses of vincristine, adriamycin and dexamethasone (VAD), and then proceeded to high-dose melphalan conditioning with an autologous peripheral blood stem cell transplant in May 2002 when his IgG was 27 g/l. Maintenance treatment with prednisone was then commenced while awaiting an HLA-identical sibling nonmyeloablative allogeneic transplant (NMAT).
His potential donor, a 52-year-old sister, however, had been diagnosed with ET in April 2002 when she presented with a platelet count of 777 Â 10 9 /l. She had persisting thrombocytosis for the preceding 4 years. Serum ferritin and C-reactive protein were normal. Abdominal ultrasound revealed a normal-sized spleen. Bone marrow aspirate and trephine (BMAT) showed a marked increase in enlarged megakaryocytes with clustering and increased nuclear lobularity. Analysis for BCR/ABL fusion gene was negative. She was commenced on hydroxyurea (HU) with improvement in platelet count to 382 Â 10 9 /l by October 2002. Ethical issues arose with regard to her suitability as a donor as well as donor safety during withdrawal of drug treatment at the time of the harvest. Ethics Committee recommendations were that the transplant could proceed if the transplant was deemed beneficial and if both donor and recipient were able to give informed consent. HU was changed to anagrelide prior to harvest. However, she could not tolerate anagrelide and HU was recommenced. HU was tailed off over 2 weeks prior to a nonprimed bone marrow harvest, which yielded 5 Â Table 1 . BMAT on Day 55 post-NMAT showed 1% plasma cells.
At presentation, the patient had marked dyslipidaemia with total cholesterol (TC) levels of 16.8, triglycerides (TG) 9.5 and high-density lipoproteins 0.50 mmol/l (Figure 1 ). Lipoprotein electrophoresis confirmed Type III hyperlipidaemia with raised intermediate-density lipoproteins and very-low-density lipoproteins. He had no family history of ischaemic heart disease, and haemoglobin A 1 c, renal, liver and thyroid function tests were all normal. His Apo E genotype was E2/E4 and not E2/E2, which is typical of Type III hyperlipidaemia. Following myeloma treatment, his lipid levels also improved with TC ranging from 5.5 to 6.0 and TG ranging from 3.7 to 5.7 mmol/l. His IgG levels remained stable post-NMAT (5.6-6. (Table 1) . Microsatellite DNA analysis using the locus D21S11 confirmed that the XO lineage was derived from the T cells of the female transplant donor.
Tacrolimus was withdrawn on Day 90 and he was commenced on thalidomide on Day 137. Donor lymphocyte infusions were not given due to a prior history of presumed Grade I acute GVHD associated with a skin rash, which resolved spontaneously. TG levels fell sharply before the introduction of thalidomide and his IgG fell to 4.7 g/l, and as predicted, the TG levels subsequently progressively decreased. BMAT examination on Day 178 post-NMAT confirmed subsequent remission with the disappearance of the XYY clone on FISH analysis. At 10 months following NMAT, the IgG monoclonal band was undetectable and BMAT carried out 18 months following transplant confirmed persisting CR and platelet numbers have remained normal without evidence of ET on BMAT.
To our knowledge, this is the first case of a successful allogeneic stem cell transplant using a donor with ET. A literature search and personal correspondence with the International Bone Marrow Transplant Registry revealed no prior cases of allogeneic transplants using donors with myeloproliferative diseases.
Hyperlipidaemia with myeloma is a rare but documented association. There have been seven case reports of myeloma-associated Type III hyperlipidaemia; four had IgA, two IgG and one IgM paraproteinaemia with two having Apo E2/E2 genotype. [1] [2] [3] [4] [5] [6] The parallel reduction in lipids in conjunction with reduced IgG levels suggests that the IgG paraprotein in this case complexed with lipoprotein particles preventing their clearance. This was confirmed by rate nephelometry following lipoprotein ultracentrifugation. The TG level in our patient has been useful in monitoring disease activity.
Conventional cytogenetics has yielded abnormalities in only 30-50% of newly diagnosed MM, but FISH analyses have increased the detection rates. Nonhyperdiploid MM is characterized by a high prevalence of IgH translocations and chromosome 13 abnormalities and portends a poorer prognosis. 7 Hyperdiploid MM, however, is associated with an improved survival, especially in the presence of certain trisomies (6, 9 and 17), 8 but chromosome abnormalities associated with myelodysplasia have a poorer prognosis. In our patient, at the time of relapse, his hyperdiploid clone showed trisomies 6 and 8, and the prognostic significance remains uncertain.
Although longer follow-up is required, this case highlights several points of considerable interest. These include the successful use of a donor with essential thrombocythaemia, a successful graft-versus-myeloma effect seen in disease with blastic morphology, the rare association of 
